Novartis Wins FDA Approval For First Symptomatic Dermographism Treatment

The U.S. FDA approved Novartis’s Rhapsido for adults with symptomatic dermographism whose symptoms remain inadequately controlled by H1 antihistamines. The approval makes Rhapsido the first FDA-approved treatment specifically for this condition; the article provides no sales estimates or market reaction.